Innova Captab Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Innova Captab Ltd trades at ₹1,147, in a confirmed uptrend and 16 weeks into that stage. That is +28.3% against its own 200-day average. It sits at 94% of a 52-week range of ₹668 to ₹1,175. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is in a confirmed uptrend — week 16 of stage 2, confirmed. At ₹1,147 it trades +28.3% versus its 200-day average and sits at 94% of its 52-week range (₹668–₹1,175).

Against the market, two honest reads. Cumulative: over the last 2.7 years the stock moved +112% while the NIFTY 500 moved +18% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Innova Captab Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: EARLY_EXPANSION. Still open: A subsequent quarter that shows Jammu reverting to negative EBITDA while consolidated revenue growth falls below management's full-year framework would break the fixed-cost-absorption thesis.

Our read, 22 August 2026. Jammu has moved to positive plant EBITDA, but the investable question is whether volume-led growth can justify a re-rated valuation after management reduced both Jammu capacity potential and Baddi capex specificity.

From the numbers. The operating cycle is in early expansion, but the deterministic normalized verdict is RE_RATED_EXPENSIVE. The current weekly PE/PB snapshot reports PE of 39.2x, 1.014x its reported median, with HEALTHY decomposition…

From the price. Price stage 2, week 16 — above its 200-day line, relative strength rising.

From the research. Jammu has moved to positive plant EBITDA, but the investable question is whether volume-led growth can justify a re-rated valuation after management reduced both Jammu capacity potential and Baddi capex specificity.

🚨 Where they disagree. The operating cycle is in early expansion, but the deterministic normalized verdict is RE_RATED_EXPENSIVE. The current weekly PE/PB snapshot reports PE of 39.2x, 1.014x its reported median, with HEALTHY decomposition and MIXED institutional signal. The normalized analysis uses trailing PE of 40.4x and finds current margins above, rather than below, through-cycle levels; normalizing earnings therefore raises the multiple to 41.4x. The favorable weekly matrix signal reflects the latest relative setup, not inexpensive normalized valuation.

What is proven. Jammu has moved to positive plant EBITDA, but the investable question is whether volume-led growth can justify a re-rated valuation after management reduced both Jammu capacity potential and Baddi capex specificity.

What is not proven yet. A subsequent quarter that shows Jammu reverting to negative EBITDA while consolidated revenue growth falls below management's full-year framework would break the fixed-cost-absorption thesis.

🚨 What would change our mind. A subsequent quarter that shows Jammu reverting to negative EBITDA while consolidated revenue growth falls below management's full-year framework would break the fixed-cost-absorption thesis.

Layer 1 read, 22 August 2026 — KEEP. The loss-making Jammu plant finally turned profitable — and the share price has been getting cheaper while earnings rise. Innova's new Jammu factory made money at the operating level for the first time this quarter, on revenue of Rs 107 crore against Rs 90 crore the quarter before — the plant's fixed costs were already being paid for, so every extra bottle now drops through. That is why profit grew 41.9% on 33.8% more revenue. What makes it a candidate rather than just a good quarter: over the last two years the shares got 17.7% CHEAPER relative to earnings while earnings per share rose 21.3%, so buyers are paying less per rupee of profit than they were, not more. The catch is that management has now cut its own capacity promises three separate times, including trimming what Jammu can eventually earn from over…

What would change Layer 1’s mind. Jammu reverting to negative plant EBITDA in the Sep 2026 quarter, or a fourth downward revision to capacity or growth guidance — either would break the fixed-cost-absorption mechanism this rests on, since the whole case is that a plant already paid for is now filling. A secondary trigger: consolidated operating margin dropping back below 15%, which would say Jammu has reintroduced a drag.

Layer 2 read, 22 August 2026 — ADVANCE. Advance cautiously: Innova is the downstream exception in a topping API sector. The Pharma-API sector is TOPPING and DIVERGENT, but its own bottom-up work says API-first companies weakened while Innova's downstream model strengthened; Jammu delivered positive EBITDA on Rs 107 crore revenue. The stock's normalized PE is a modelled 90th-percentile reading [C006, evidence_grade=model], yet Jun revenue and profit rose 33.8% and 41.9%. Capacity promises were cut, so ADVANCE is capped by credibility and needs another reported quarter, not another forecast.

What would change Layer 2’s mind. A reported quarter showing Jammu back in negative EBITDA while consolidated revenue growth falls below the retained 20% FY27 framework would flip this ADVANCE to BENCH or DROP.

Layer 3 read, 22 August 2026 — DEPLOY. Jammu is finally profitable and Baddi is now approved, but the reporting correction keeps the size small. Stream 5 partly MITIGATES Timeline R3: the board approved a concrete Baddi brownfield project. A same-day filing REVEALS a new governance concern because FY26 audited statements were revised for errors, although the audit opinion stayed unmodified. Jammu's positive EBITDA keeps the thesis intact, while three recent guidance misses cap management at WATCHLIST and size at 1.5%.

What would change Layer 3’s mind. A later filing that turns the FY26 account revision into an audit qualification or confirmed control failure would flip DEPLOY to DROP.

CIO read, 22 August 2026 — BENCH. NOT ADMITTED (incoming, benched) · forward-asymmetry 56/100 · CONTESTED. Judged EPS growth of 24.0% only just covers the model-implied 23.3%, leaving a derived +0.7-point gap. The rating is normal at the 50th percentile, and three capacity or spending promises were missed or cut, so it needs a fight even in the DEPLOY regime.

The test written in advance. A subsequent quarter that shows Jammu reverting to negative EBITDA while consolidated revenue growth falls below management's full-year framework would break the fixed-cost-absorption thesis. — the thesis as written as stated by the next result.

The test written in advance. Re-rated valuation — Re-rated valuation Reported earnings growth versus the retained FY27 revenue framework. by the next result.

The test written in advance. Jammu capacity economics revised lower — Jammu capacity economics revised lower Jammu revenue and EBITDA disclosed in the next concall. by the next result.

What the company does. The latest quarter delivered revenue and profit growth while Jammu reported positive EBITDA for the first time. Management retained the full-year revenue framework and expects profit growth to exceed revenue growth as utilization rises. The valuation is not a trough-margin bargain: normalized earnings leave the multiple higher, while reduced Jammu revenue potential and a softened Baddi plan limit the margin for execution error.

🚨 What the surface reading misses. The surface reading is: A high trailing PE can suggest an expensive stock. The research reads it further: The deterministic normalized analysis shows that operating margin is not depressed, so normalizing earnings does not reveal hidden cheapness.

🚨 What the surface reading misses. The surface reading is: The trailing multiple looks elevated. The research reads it further: Normalizing margin does not improve valuation because current margin is above the through-cycle reference.

Lever 1 · Operating leverage — BUILDING. Jammu reported positive plant EBITDA as quarterly revenue rose, providing the first direct evidence that utilization can convert fixed costs into profit. What proves it keeps working: Jammu fixed-cost absorption. It stops working if Jammu reports negative EBITDA again or revenue traction stalls despite completed approvals.

Lever 2 · Value-added mix — BUILDING. Management cited volume growth, new customers and deeper wallet share as the primary sources of current growth. What proves it keeps working: Volume-led CDMO and branded-generics growth. It stops working if Customer onboarding or wallet-share expansion fails to convert into reported consolidated revenue growth.

Lever 3 · Management change — BUILDING. Completed approvals and expanding ROW coverage can increase the addressable customer base for Jammu and export products. What proves it keeps working: Regulated-market approvals. It stops working if Approvals do not translate into audits, onboarding or visible Jammu revenue.

Lever 4 · Paying down debt — BUILDING. Management now frames growth capex around existing capabilities and debottlenecking rather than a confirmed Baddi greenfield build. What proves it keeps working: Existing-capacity debottlenecking. It stops working if The board-approved plan remains absent and debottlenecking does not add measurable capacity or revenue.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Innova Captab Ltd reported ₹471 Cr of revenue in the Jun 26 quarter, +33.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 7 years it has compounded at 24.3% a year. The last full year, FY26, came in at ₹1,630 Cr. The last four reported quarters add to ₹1,749 Cr.

FY26 revenue came in at ₹1,630 Cr (+31.0% on the year), capping 7 years at 24.3% compound. The latest quarter (Jun 26) printed ₹471 Cr, +33.8% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +34.5% growth against the decade's 24.3% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +34.4% over the last 4 quarters against +23.8%/yr over the last 8 — accelerating; TTM profit +18.5% vs +20.5%/yr — stabilising.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Innova Captab Ltd's operating margin is 16.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 8 fiscal years the operating margin has ranged 11.0% to 15.0%. The current quarter is running above every full year in that window.

Why this happened. The operating-leverage catapult applies only if plant EBITDA stays positive as volumes scale. Management attributes the mechanism to customer and product onboarding, audits and dossier approvals; the current print is evidence, not a completed facility-level return profile.

The latest quarter's operating margin is 16.0%, +1.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 11.0%–15.0%, and FY26's 15.0% is the top of that band — a record year.

Why the margin moved: operating margin went +0.7 pp year on year while gross margin went −1.8 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Innova Captab Ltd earned ₹44.0 Cr of net profit in the Jun 26 quarter, +41.9% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹141 Cr. The 7-year compound rate is 32.2%. That is 9.3% of the quarter's revenue. The same quarter a year earlier earned ₹31.0 Cr.

Jun 26 profit was ₹44.0 Cr, +41.9% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹141 Cr (+10.2%), and the 7-year compound rate is 32.2%.

Why profit moved: revenue contributed +33.8% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +19.4% vs revenue +34.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 90% of Innova Captab Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹117 Cr of operating cash against ₹141 Cr of profit. After ₹50.0 Cr of capital spending, ₹67.0 Cr was left as free cash.

FY26: operating cash of ₹117 Cr against reported profit of ₹141 Cr, leaving free cash of ₹67.0 Cr after ₹50.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 90% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 90%: the cash cycle tightened 17 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 8.6× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Innova Captab Ltd's cash conversion cycle runs 82 days in FY26, down from 99 days in FY21. Capital spending ran ₹739 Cr over the last 3 years. At FY26 sales of ₹1,630 Cr each day of that cycle holds about ₹4.5 Cr, so roughly ₹366 Cr sits inside the business at any moment.

FY26: debtors at 98 days, inventory at 125 days — roughly 4.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 82 days, tighter than FY21's 99.

The full loop: cash goes out to suppliers and production on day 0; stock waits 125 days to sell; customers pay about 98 days after that; and suppliers themselves are paid at 141 days — netting out to the 82-day cycle.

In money terms: at FY26 sales of ₹1,630 Cr, each day of the cycle holds about ₹4.5 Cr — so the 82-day loop keeps roughly ₹366 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹739 Cr over the last 3 fiscal years against ₹86.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹16.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Innova Captab Ltd earns a ROCE of 15% in FY26. Return on invested capital clears the cost of that capital by −0.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 8.7% net margin on 0.89× asset turns.

FY26 ROCE is 15%.

🚨 Why the return is what it is — the wiring (FY26): 8.7% net margin × 0.89× asset turns × 1.68× balance-sheet leverage ≈ 13.0% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 11.4% − 12.0% = a −0.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Innova Captab Ltd carries total debt of ₹344 Cr against shareholder equity of ₹1,091 Cr as of Mar 26, a debt-to-equity of 0.32. On the annual view that ratio went from 0.95 in FY22 to 0.32 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Why this happened. This route can support nearer-term growth with lower capital intensity, but it also removes the certainty of the earlier Baddi capacity plan. The driver is conditional on a board-approved scope or disclosed execution milestones.

Mar 26: total debt of ₹344 Cr against shareholder equity of ₹1,091 Cr — a debt-to-equity of 0.32. On the annual view, debt-to-equity went from 0.95 (FY22) to 0.32 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions cut 1.3 points of Innova Captab Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.9% of the company. Foreign institutions moved −0.8 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

Why this happened. The regulatory-unblocking catalyst is relevant because management cites completed PIC/S approval, further ROW and European product approvals, and customer onboarding as the bridge from capacity to revenue.

The register over the last two years — Domestic institutions: −1.3 points over 8 quarters to 19.9%; Foreign institutions: −0.8 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 50.9%.

🚨 Why the register moved: domestic institutions drove it (−1.3 points), alongside foreign institutions (−0.8 points) — distribution into the market’s bid.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Innova Captab Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Innova Captab Ltd trades at 42.6× P/E, at the pricey end of its own range (90th percentile). Its long-run median P/E is 38.1×, measured across 2.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 42.6× is at the pricey end of its own range (90th percentile), against a long-run median of 38.1× measured over 2.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +9.9% against a +33.5% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 25 August 2026 price, Innova Captab Ltd was paying for profit growth of about 23.3% a year. Profit itself has compounded 32.2% a year over the past 7 years. Today the market pays 42.6× P/E, the 90th percentile of its own 3-year range.

What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 25 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Innova Captab Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 16.1% and holding. The read is built from 11 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

4-Factor Sector Score

57.7/100 — rank 3 of 14 in Pharma - API · 100% evidence confidence

Innova Captab Ltd scores 57.7 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 24.8 + 13.2 + 5.9 + 13.8 = 57.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Innova Captab Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Baddi Expansion Plan Materially Softened · 12 August 2026. In May 2026, management described the new Baddi block as a planned FY27-FY28 project with an expected capital outlay of INR150-170 crores. In Aug 2026, management instead described growth capex of only around 20-30 crores for debottlenecking and existing capabilities, while stating that the Baddi plot plan was still at a baseline stage; no explanation was provided for the apparent retreat in commitment and timing.

🚨 Jammu Revenue Potential Reduced · 12 August 2026. The latest call lowered the stated optimum revenue potential of the Jammu facility from around INR1,400 crores plus to INR1,000-1,200 crores. The latest range is materially below the prior indication, including a lower utilization range, and management did not explain the change in the facility's expected economics.

🚨 Q4 FY26 Jammu Sequential Ramp-up Not Delivered Despite Explicit Prior Quarter Optimism · 8 May 2026. In the Jan 2026 prepared remarks, management specifically expressed optimism about a Jammu operational ramp-up in the coming quarter (Q4 FY26), which carried credibility given the strong Q3 sequential jump from approximately Rs. 60 crores per quarter in H1 to Rs. 89 crores. In the May 2026 call, management revealed the Q4 Jammu exit run rate was only 90 crore plus - approximately Rs. 91 crores and essentially flat versus Q3's Rs. 89 crores - representing under 2% sequential growth with no meaningful ramp-up. Management offered no explanation in the May 2026 call for why the Q4 acceleration that was specifically guided for in the prepared remarks failed to materialize.

Jammu Facility Revenue Guidance Cut · 27 January 2026. In the August 2025 call, management explicitly guided for ₹400 crores in revenue from the Jammu facility for the current financial year. However, in the January 2026 call, this target was significantly lowered to a range of ₹270-280 crores, representing a ~30% reduction from the initial expectation. Earlier call (Aug 2025): “The Jammu revenue anticipated for this financial year as we submitted in our earlier discussions is ₹ 400 crores.” Later call (Jan 2026): “For this year, we would like to maintain that guidance... it will remain in the range of 270-280 crores.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions